CTLA4 and neoplasm: Furthermore, in one study, NK-cell dysregulation and cytotoxicity were restored in patients with mesothelial carcinoma treated with the monoclonal antibody against CTLA4, telemumab, indicating that blockade of CTLA4 prevents NK-cell dysfunction, slows tumor growth, and improves overall survival among patients with tumors (58).